OnKure Therapeutics, Inc. (OKUR) intrinsic value & 10-year financials
OnKure Therapeutics, Inc. (OKUR) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.10
- Market cap
- $28.4M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 245.2%
- Free cash flow (FY2025)
- -$51.9M
OKUR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$59.5M | -$4.40 | -$51.9M | — | 1361.1% |
| FY2024 | $0 | -$52.7M | -$3.82 | -$51.2M | — | -197.6% |
| FY2023 | — | -$77.4M | -$0.63 | -$63.9M | — | -116.5% |
| FY2022 | — | -$52.0M | -$0.53 | -$47.7M | — | -66.4% |
| FY2021 | — | -$39.8M | -$0.55 | -$38.2M | — | — |
| FY2020 | — | -$19.5M | -$0.27 | -$18.6M | — | — |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
OnKure Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
OnKure Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -42.8% ROIC.
OnKure Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
OnKure Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.